María del Rosario
García Campelo
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicacións en colaboración con investigadores/as de AstraZeneca (United Kingdom) (3)
2021
-
DUART: Durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy
Future Oncology, Vol. 17, Núm. 34, pp. 4657-4663
-
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 1, pp. 51-65
2020
-
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148